James Bennett Jr., M.D., PH.D. is Affiliate Clinical Professor of Neurology at Virginia Commonwealth University, President of Neurodegeneration Therapeutics, Inc., a nonprofit laboratory in Charlottesville, Virginia, ALS Worldwide’s Chief Scientific Officer, and Lead US Investigator for MicroNeurotrophin Drug Development. Dr. Bennett is also the Physician Sponsor to the FDA on behalf of the ALS Worldwide Research Consortium. In preclinical studies, he led the testing of MicroNeurotrophin drugs in human neural cells. Dr. Bennett holds multiple patents related to additional therapies he has developed for neurodegenerative diseases.
Pamela Shaw, DBE MBBS MD FRCP FAAN FANA FMedSci is Director of the Sheffield Institute for Translational Neuroscience (SITraN) and Professor of Neurology at the University of Sheffield. She oversaw testing of MicroNeurotrophin drugs in zebrafish animal models and mouse nerve cells co-cultured with glial cells (astrocytes) derived from humans with genetic or sporadic ALS. In 2013, In 2013, Professor Shaw was awarded the Dame Commander of the Order of the British Empire (DBE) for services to Neuroscience in Her Majesty the Queen’s New Years’ Honors.
Ghazaleh Sadri-Vakili, PH. D. is Director of the NeuroEpigenetics Laboratory at Massachusetts General Hospital and Assistant Professor of Neurology at Harvard Medical School. She led the testing of MicroNeurotrophin drugs using an ALS mouse model. Dr. Sadri-Vakili has authored multiple publications in the fields of epigenetics, neurodegeneration, and drug addiction.
Achilleas Gravanis, PH.D., Professor of Pharmacology at University of Crete’s School of Medicine, is the co-developer of MicroNeurotrophins. Dr. Gravanis has continued his groundbreaking work on MicroNeurotrophins, leading his laboratory while providing technical assistance to the other members of the research team.